Fmoc-Thr[GalNAc(Ac)3-α-D]-OH

Fmoc-Thr[GalNAc(Ac)3-α-D]-OH is a specialized glycosylated amino acid derivative designed for advanced peptide synthesis and glycopeptide research. Featuring an Fmoc-protected threonine backbone conjugated with a triacetylated N-acetyl-α-D-galactosamine (GalNAc) moiety, this compound enables precise incorporation of O-linked glycosylation motifs into peptide chains. Its unique structure closely mimics natural mucin-type glycosylation patterns, making it a valuable tool for investigating the structural and functional roles of glycosylation in biological systems. Researchers utilize this building block to explore glycoprotein biosynthesis, protein-carbohydrate interactions, and the development of synthetic glycopeptide libraries for biochemical and biophysical studies.

Glycopeptide Synthesis: As a protected glycosylated amino acid, Fmoc-Thr[GalNAc(Ac)3-α-D]-OH is widely employed in solid-phase peptide synthesis (SPPS) to introduce site-specific O-linked GalNAc glycosylation. The Fmoc protection allows for sequential peptide elongation, while the triacetylated GalNAc side chain ensures stability during synthesis and subsequent deprotection steps. This capability is essential for constructing homogeneous glycopeptides that accurately recapitulate natural glycosylation sites, facilitating the study of structure-function relationships in glycoproteins and the creation of defined glycopeptide standards for analytical applications.

Glycobiology Research: The compound plays a pivotal role in elucidating the biological significance of mucin-type O-glycosylation. By enabling the synthesis of peptides bearing the Tn antigen (GalNAc-α-O-Thr), it supports investigations into how specific O-glycan modifications influence protein folding, stability, and cellular recognition processes. Such studies are critical for understanding the molecular mechanisms underlying cell-cell communication, immune recognition, and the progression of various diseases where aberrant glycosylation is implicated.

Protein-Interaction Studies: Incorporation of this glycosylated threonine derivative into synthetic peptides allows researchers to probe protein-carbohydrate interactions with high specificity. These model glycopeptides serve as valuable substrates for binding assays, enabling the identification and characterization of lectins, antibodies, or enzymes that recognize O-GalNAc-modified motifs. Insights gained from these studies inform the design of glycan-targeting probes, inhibitors, or affinity reagents for use in biochemical and diagnostic research.

Analytical Method Development: The defined structure of Fmoc-Thr[GalNAc(Ac)3-α-D]-OH facilitates the generation of glycopeptide standards for use in mass spectrometry, HPLC, and other analytical platforms. Such standards are crucial for the accurate detection, quantification, and characterization of glycopeptides in complex biological samples. By providing a reliable reference, this compound aids in the development and validation of glycoproteomics workflows, supporting advances in the identification and mapping of glycosylation sites across diverse proteomes.

Synthetic Glycoconjugate Design: Beyond its applications in peptide synthesis, the compound offers utility in the creation of synthetic glycoconjugates for functional studies. Researchers leverage its modular structure to design vaccines, biomaterials, or molecular probes that display defined O-linked GalNAc motifs. These constructs are instrumental in dissecting glycan-mediated biological processes, evaluating immune responses to glycopeptide antigens, and developing new tools for glycan-targeted research in chemical biology and biotechnology.

1. Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore

2. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

5. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury